

Innovative Formulations and Processing Technologies for Oral Drug Delivery

Oral drug delivery remains one of the most important and widely adopted routes of administration in pharmaceutical development. Tablets and capsules continue to offer clear advantages in terms of patient acceptance, convenience, stability, scalability and cost-effective manufacture. Yet the science behind oral dose development has changed significantly. Today's oral medicines are increasingly expected to do more than deliver an active ingredient in a conventional immediate-release format. They must overcome solubility and bioavailability limitations, support challenging drug substance properties, enable modified or targeted release, align with paediatric and patient-centric needs and transition efficiently from early clinical supply to commercial-scale manufacture.

This evolution is being driven by the changing nature of pharmaceutical pipelines. Many contemporary small molecule candidates present formulation challenges, particularly poor aqueous solubility, limited permeability, complex solid-state behaviour or potency-related handling requirements. Poor solubility remains one of the most persistent barriers in drug development, making early understanding of API characteristics essential to maximising solubility, stability and therapeutic impact. At the same time, the industry is seeing increased interest in more complex oral dosage forms, including modified-release systems, paediatric-friendly presentations, liquid-filled capsules, amorphous solid dispersions and other enabling technologies designed to improve *in vivo* performance.

For drug developers, the key question is no longer simply whether a compound can be made into a tablet or capsule. It is whether the selected formulation and process are sufficiently robust, scalable and clinically appropriate to support the product across its lifecycle. That requires a development strategy that integrates formulation science, material understanding, process engineering, analytical capability and regulatory foresight from the outset.

Oral Delivery Remains Central – But Expectations Are Rising

The continued dominance of oral solid dosage forms reflects their practical value. They are generally easier for patients to take than injectable therapies, comparatively stable during storage and distribution and suitable for large-scale production. However, the simplicity perceived by patients often masks the complexity involved in development and manufacture. As pipelines have shifted towards more challenging molecules, the oral dosage form has had to become more sophisticated.

Recent industry analysis points to sustained growth in oral solid dose development, with innovation focused on improving drug efficacy, adherence and manufacturability through advanced delivery systems, modified-release technologies and formulation platforms that address bioavailability challenges. The sector is also seeing increased demand for CDMO support across formulation development, testing, analytical services, clinical supply and manufacturing as companies seek specialist expertise to manage greater technical complexity.

In practical terms, this means oral dose development must balance speed with scientific depth. Early clinical programmes often require rapid delivery of fit-for-purpose formulations for first-in-human studies, while later-phase programmes require deeper product and process understanding, control strategies and scale-up pathways. The most successful programmes are those in which these requirements are not treated as separate phases, but as part of a continuous development pathway.

The rise of targeted therapies and precision medicines is reshaping oral dose manufacturing. As products are increasingly developed for smaller patient populations, commercial volumes are often significantly lower than those associated with traditional blockbuster drugs. In response, manufacturers are adopting more flexible, small-scale production models, often utilising equipment and technologies traditionally associated with development-phase manufacturing.

CDMOs have been at the forefront of this transition, investing in flexible infrastructure,

advanced processing technologies and contained high-potency capabilities that enable the efficient manufacture of small-volume, high-value medicines while supporting seamless progression from development to commercial supply.

Bioavailability Enhancement: Addressing a Critical Development Challenge

One of the most prominent areas of innovation in oral drug delivery is bioavailability enhancement. A high proportion of new chemical entities present poor aqueous solubility, which can limit absorption and make it difficult to achieve therapeutic exposure through conventional formulations. In these cases, simple blending, granulation and compression may not be sufficient. Instead, more advanced formulation strategies may be required to improve dissolution rate, maintain supersaturation, stabilise amorphous forms or enhance absorption.

Amorphous solid dispersions, spray drying, hot melt extrusion, particle engineering, lipid-based systems and liquid-filled capsules are among the technologies increasingly used to address solubility and exposure challenges. Industry commentary has highlighted amorphous solid dispersions prepared through spray drying or hot melt extrusion as important tools for improving solubility and bioavailability in oral solid dosage development. These technologies are not interchangeable; each has advantages, constraints and development implications. Selection should be based on compound properties, target dose, stability profile, manufacturability, clinical objectives and commercial considerations.

For example, spray drying can be valuable where rapid solvent removal is needed to generate an amorphous dispersion with improved dissolution characteristics. Hot melt extrusion may be suitable where the API and polymer system can withstand thermal and mechanical processing.

Liquid-filled capsules, semi-solid-filled hard capsules and non-sterile oral liquids can provide efficient early-phase solutions for poorly soluble compounds, particularly where speed to clinic is a priority. Particle size reduction or other particle engineering

techniques may be appropriate where dissolution rate, content uniformity or downstream processability are limiting factors.

The scientific challenge lies not only in selecting a technology, but in understanding the formulation system. Polymer selection, drug loading, residual solvent control, physical stability, recrystallisation risk, dissolution behaviour and scale-up feasibility must all be considered. The formulation must be robust enough to support clinical supply, but also capable of evolving into a commercially viable product.

Processing Technologies: Where Formulation Meets Manufacturability

Innovative formulation design must be matched by appropriate processing technology. Oral drug delivery success depends on the ability to manufacture a product reproducibly, at the right quality, and at the required scale. This is particularly important for complex formulations, highly potent compounds or products requiring tight control of critical quality attributes such as dissolution, assay, content uniformity, impurity profile, stability or release performance.

Traditional oral solid dose processes, including blending, granulation, compression, encapsulation and coating, remain essential. However, the level of process understanding required has increased. Developers must understand how material attributes and process parameters influence product performance. This deeper understanding has also enabled the incorporation of novel and functional excipients that can enhance product performance while maintaining robust and reproducible manufacturing processes.

This includes properties such as particle size distribution, polymorphic form, flowability, glass transition temperature, compressibility, moisture sensitivity and excipient compatibility. It also includes process variables such as mixing time, granulation endpoint, drying conditions, compression force, coating parameters and environmental controls.

Advanced processing approaches can help address specific development challenges. Wet granulation may improve flow and content uniformity for low-dose products. Dry granulation can be advantageous for moisture- or heat-sensitive compounds. Coating technologies can support taste

masking, moisture protection, enteric release or modified-release performance.

Encapsulation may provide flexibility during early development, especially where dose range exploration is required. For potent compounds, contained processing and appropriate facility design are central to operator safety, product quality and cross-contamination control.

Quality by Design and the Move Towards Deeper Product Understanding

The regulatory and scientific direction of travel is clear: quality should be built into the product and process, not tested in at the end. ICH Q8(R2) provides a framework for pharmaceutical development and describes how greater understanding of formulation and manufacturing sciences can support flexible regulatory approaches. The FDA's Q8(R2) guidance further describes the principles of Quality by Design, including the value of development knowledge and process understanding.

For oral dosage forms, Quality by Design begins by defining the Quality Target Product Profile. What should the product do? What dose, release profile, stability, presentation and patient requirements must it meet? From there, developers identify critical quality attributes and assess which material attributes and process parameters may influence them. Design of experiments, risk assessment, predictive modelling and analytical characterisation can then be used to build a more complete understanding of the product and process.

This approach is particularly valuable when dealing with complex oral formulations. For a bioavailability-enhanced product, for example, the critical quality attributes may include amorphous content, dissolution profile, residual solvent, particle morphology, impurity formation and physical stability. For a modified-release tablet, they may include release rate, coating uniformity, tablet hardness, friability and robustness under different physiological conditions. For a highly potent product, containment, cleaning strategy and cross-contamination control become central to the development plan.

A QbD approach does not necessarily mean longer timelines. In many cases, it can reduce risk by identifying potential failure points earlier, avoiding repeated reformulation and supporting more efficient scale-up. The value is in making development decisions based on scientific evidence rather than trial and error.

Analytical Science as an Enabler of Oral Dose Innovation

Analytical capability is often the unsung enabler of successful oral drug delivery. Innovative formulations require robust methods to characterise both the API and finished dosage form. This may include solid-state characterisation, assay and impurity testing, dissolution method development, stability studies, content uniformity, residual solvent analysis, water content, particle size analysis and physical characterisation of intermediate materials.

For amorphous solid dispersions, analytical science is essential to confirm amorphous form, detect recrystallisation, monitor stability and understand dissolution behaviour. For modified-release formulations, discriminatory dissolution methods are critical to link in vitro performance with product quality and, where possible, *in vivo* behaviour. For paediatric formulations, analytical methods must often support dose flexibility, taste-masking assessment, stability and compatibility with administration routes. For potent compounds, analytical procedures must be aligned with containment and safe handling requirements.

Patient-Centric Formulation: Beyond Manufacturability

Innovation in oral drug delivery is not solely about overcoming technical development barriers. It is also about improving the patient experience. Patient-centric dosage form design considers how the medicine will be used in real life, including swallowability, dose burden, taste, dosing frequency, packaging, administration with food or liquids, and suitability for paediatric, geriatric or other specialist populations.

Modified-release technologies can reduce dosing frequency and support adherence. Mini-tablets, multiparticulates, oral liquids or sprinkle formulations may help paediatric or dysphagic patients. Taste masking can be decisive for adherence, particularly in children. Smaller tablet size, improved coating or alternative capsule formats may make a meaningful difference for patients managing chronic therapy.

The challenge is that patient-centric features must be scientifically and commercially feasible. A formulation that is ideal for the patient but unstable, difficult to manufacture or hard to scale will struggle to progress. Conversely, a formulation that is easy to manufacture but poorly suited to patient needs may not deliver the intended

therapeutic benefit in practice. The optimum development strategy therefore considers patient use, product performance and manufacturing reality together.

This is especially important for products intended to move from early phase to commercialisation. Early development formulations may be fit for initial clinical assessment, but developers should maintain a view of the likely commercial presentation. Decisions around excipients, capsule versus tablet, liquid versus solid, release profile and packaging should be informed by the long-term target product profile wherever possible.

Scalability: Designing with the End in Mind

A recurring challenge in oral drug delivery is the transition from small-scale development to larger-scale GMP manufacture. A process that works well at laboratory scale may behave differently when batch size, equipment geometry, mixing dynamics, drying efficiency or compression speed changes. Scale-up risk can be particularly significant for complex formulations, low-dose products, poorly flowing materials, moisture-sensitive APIs or modified-release systems.

Where precision medicines is driving towards lower commercial volume this is influencing how scalability is defined. Rather than simply increasing batch size, developers must ensure processes remain robust across smaller manufacturing scale and equipment. Flexible equipment platforms and process design are enabling efficient production for targeted therapies, orphan medicines and other lower-volume products, while maintaining the quality, control and supply reliability expected of commercial manufacture.

Designing with scalability in mind does not mean over-engineering early clinical formulations. It means making informed choices that preserve future options. For example, selecting excipients with a strong regulatory and supply track record, understanding whether a process is likely to be transferable, choosing analytical methods capable of supporting later-phase control strategies, and documenting development rationale clearly.

The Role of Partnership in Modern Oral Dose Development

As oral formulations become more complex, the role of the CDMO is also changing. Sponsors are not simply looking for capacity; they are looking for scientific input, problem-



solving, regulatory awareness and practical manufacturing experience. The most effective partnerships are built around transparent technical dialogue. This includes early discussion of molecule properties, clinical objectives, dose projections, formulation risks, timelines, regulatory expectations and commercial ambitions.

A capable CDMO should be able to challenge assumptions constructively. Is an immediate-release capsule sufficient for first-in-human studies, or is an enabling technology required? Is the selected bioavailability approach scalable? Are there stability risks that should be addressed before GMP manufacture? Is the analytical method sufficiently discriminatory? Can the process accommodate future dose strengths? Are there containment implications? What data will be needed to support regulatory submissions?

These questions are not barriers to progress; they are safeguards against avoidable development risk. In oral drug delivery, speed is important, but speed without scientific understanding can create costly delays later. A disciplined development strategy can support both efficiency and robustness.

Looking Ahead: A More Integrated Future for Oral Drug Delivery

The future of oral drug delivery will be shaped by continued innovation in formulation science, processing technologies, data-driven development and patient-centric design. Artificial intelligence, predictive modelling and digital tools are expected to play a greater role in formulation screening and process optimisation, although these tools will need to be grounded in high-quality experimental data and practical manufacturing knowledge.

However, the fundamentals will remain the same. A successful oral medicine must deliver the right dose, at the right rate, with

consistent quality, in a form that patients can use and manufacturers can reliably produce. Innovation is valuable when it solves a real development or patient problem. The goal is not complexity for its own sake, but purposeful formulation and process design.

For companies developing oral medicines, the opportunity lies in integrating enabling technologies earlier, applying QbD principles pragmatically and selecting experienced development partners with the scientific and operational capability to support the product across its lifecycle. As pipelines continue to challenge conventional formulation approaches, this integrated model will become increasingly important.

Advances in formulation science and processing technology are enabling developers to address increasingly complex molecules while delivering robust, scalable and patient-centric oral medicines.

Oral drug delivery has always been central to pharmaceutical development. What is changing is the level of science required to make oral delivery work for today's molecules and tomorrow's patients. Through advanced formulation technologies, robust processing strategies and lifecycle-focused development, the industry can continue to expand what is possible through the oral route – delivering medicines that are not only manufacturable, but meaningful for the patients who depend on them.



**Sander
van den Ban**

Director | Operations, Manufacturing,
Almac Pharma Services